Novel Immunotherapies for Diffuse Large B-Cell Lymphoma
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: 20 March 2026 | Viewed by 103
Special Issue Editor
Interests: B-cell lymphoma; T-cell lymphoma; high-grade B-cell lymphoma (HGBCL); Burkitt lymphoma (BL); diffuse large B-cell lymphoma (DLBCL); angioimmunoblastic T-cell lymphoma (AITL); T-follicular helper-like
Special Issue Information
Dear Colleagues,
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma, characterized by remarkable biological heterogeneity and diverse clinical outcomes. Although standard immunochemotherapy regimens such as R-CHOP have improved survival, a significant proportion of patients experience relapse or refractory disease, underscoring the urgent need for innovative therapeutic strategies. In recent years, novel immunotherapies have transformed the treatment landscape, offering new hope for patients with limited options.
Advances in CAR-T cell therapies, bispecific antibodies, immune checkpoint inhibitors, and antibody–drug conjugates have demonstrated promising efficacy in relapsed/refractory DLBCL. At the same time, insights from genomic, transcriptomic, and tumor microenvironment studies are guiding the development of more precise immune-based interventions. These approaches not only target malignant B cells but also modulate immune evasion pathways, highlighting the central role of the immune system in disease progression and treatment response.
This Special Issue, “Novel Immunotherapies for Diffuse Large B-Cell Lymphoma”, will bring together cutting-edge original research, comprehensive reviews, and translational insights that explore new immunotherapeutic avenues. We invite contributions spanning molecular mechanisms, preclinical models, biomarker discovery, and translational applications, with the goal of advancing precision medicine and improving patient outcomes in DLBCL.
Dr. Waseem Lone
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- diffuse large B-cell lymphoma
- immunotherapy
- CAR-T cells
- bispecific antibodies
- immune checkpoint inhibitors
- antibody–drug conjugates
- tumor microenvironment
- biomarkers
- translational research
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
